## Contact Information

Bethesda MD20892

hanna.kim@nih.gov

## Media Resources

High Resolution Image

## Summary

Hanna Kim, M.S., M.D., is a board-certified pediatric rheumatologist who is focused on exploring pathogenesis and novel treatments in juvenile dermatomyositis. During her rheumatology fellowship, Dr. Kim developed a passion for clinical and translational research while studying interferon-mediated autoinflammatory diseases, novel biomarkers, pharmacokinetics, and pharmacodynamics, and safety and efficacy in a compassionate use study with an investigational drug. She went on to become a Lawrence Shulman Scholar and studied the role of interferon and activity-related biomarkers in myositis, particularly juvenile dermatomyositis. She has also been evaluating Janus kinase inhibition in a compassionate use program for refractory juvenile dermatomyositis.

Dr. Kim was appointed as an Assistant Clinical Investigator in 2020 and is also an attending physician on the NIH Pediatric Rheumatology Consultation Service. She is actively involved in a range of organizations including the American College of Rheumatology (ACR), the Childhood Arthritis Rheumatology Research Alliance, and the International Myositis Assessment and Clinical Studies Group.

She has received numerous local, national, and international awards and honors, including NIAMS Group Merit Award, ACR Distinguished Fellow Award, Rheumatology Research Foundation Pediatric Research Award, Pediatric Rheumatology European Society Young Investigator Travel Award, selection for the ACR-European League Against Rheumatism Early Investigator Exchange Program, and best abstract at the Global Conference on Myositis. Dr. Kim has also given national and international presentations.

## Research Statement

The Juvenile Myositis Therapeutic and Translational Studies Unit is a research group focused on better understanding the pathogenesis of juvenile myositis, particularly inflammatory and immune mechanisms, and improved therapy. This is approached by discovery biomarker analysis utilizing broad expression such as transcriptomic and proteomic analysis in juvenile dermatomyositis, a rare autoimmune system vasculopathy with notable involvement of skin with characteristic rashes and muscle inflammation.  Another approach is looking at how biomarkers in juvenile myositis compare to Mendelian autoinflammatory disease and further analysis of juvenile myositis separated by myositis autoantibody subgroups which have some distinct patterns of features.

Regarding treatment, we investigate novel treatments in small clinical trials in juvenile myositis with the goal of establishing more targeted therapy ideally with fewer side-effects and greater efficacy.  We hope that through better understanding pathogenesis can be paired with the investigation of novel therapies that can lead to better management and improved quality of life for people with juvenile myositis.

## Scientific Publications

###             Insights into juvenile myositis via engineered muscle.        

19(9).

###             Improvement in Disease Activity in Refractory Juvenile Dermatomyositis Following Abatacept Therapy.        

75(7).

###             Performance of the 2016 ACR-EULAR Myositis Response Criteria in adult dermatomyositis/polymyositis therapeutic trials and consensus profiles.        

62(11).

###             Performance of the 2016 ACR-EULAR myositis response criteria in juvenile dermatomyositis therapeutic trials and consensus profiles.        

62(11).

###             Urine proteomics by mass spectrometry identifies proteins involved in key pathogenic pathways in patients with juvenile dermatomyositis.        

62(9).

###             Improvement in Disease Activity in Refractory Juvenile Dermatomyositis Following Abatacept Therapy.        

75(7).

###             Treatment escalation patterns to start biologics in refractory moderate juvenile dermatomyositis among members of the Childhood Arthritis and Rheumatology Research Alliance.        

21(1).

###             Updates on Juvenile Dermatomyositis from the Last Decade: Classification to Outcomes.        

47(4).

###             Updates on interferon in juvenile dermatomyositis: pathogenesis and therapy.        

33(5).

###             Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis.        

80(3).

###             Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies.        

22(1).

###             Development of a Validated Interferon Score Using NanoString Technology.        

38(4).

###             Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients.        

104(2).

###             JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.        

128(7).

###             Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America.        

15(1).

###             Insights from Mendelian Interferonopathies: Comparison of CANDLE, SAVI with AGS, Monogenic Lupus.        

94(10).

## Education

**University of California at Irvine (UCI)**M.D.

**Virginia Commonwealth University (VCU)**M.S.

**California Institute of Technology (Caltech)**B.S.

## Experience

**Lawrence Shulman Scholar in Translational Research**NIAMS, NIH, Bethesda, MD

**Residency in Pediatrics**George Washington University / Children’s National Medical Center

**Pediatric Rheumatology Fellowship**Nemours/Alfred I. DuPont Hospital for Children (Wilmington, DE), Children’s National Health System (DC), and NIAMS, NIH.

August 2023

Back to Top